

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (previously presented): 5-Chloro-2-(1-homopiperazinyl)-7-methylbenzoxazole or a salt thereof.

2-17. (canceled).

18. (previously presented): A pharmaceutical composition which comprises, as an active ingredient, an effective amount of a substance selected from the group consisting of the compound according to claim 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof.

19. (previously presented): A method for the manufacture of the pharmaceutical composition according to claim 18, which comprises mixing the substance selected from the group consisting of 5-chloro-2-(1-homopiperazinyl)-7-methylbenzoxazole, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof, with a pharmaceutical carrier.

20. (previously presented): A method for therapeutic treatment of condition of irritable bowel syndrome or digestive tract functional disorder, or condition of diarrhea, which comprises a step of administering to a mammal including human a therapeutically effective amount of a substance selected from the group consisting of the compound according to claim 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof.

21. (currently amended): A serotonin 5-HT₃ receptor antagonistic agent or partial activator for therapeutic treatment of condition of irritable bowel syndrome or digestive tract functional disorder, or condition of diarrhea, comprising as an active ingredient, an effective

AMENDMENT

U.S. Appln. No. 09/856,372

amount of a substance selected from the group consisting of ~~the compound according to claim 1~~
5-chloro-2-(1-homopiperaziny)-7-methylbenzoxazole, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof.

22-24. (canceled).